Business Context and Reporting Period
This Form 8-K reports on the special meeting of stockholders held by Salarius Pharmaceuticals, Inc. on July 8, 2025. The filing details the voting results for three proposals submitted to shareholders. As of the record date (May 13, 2025), there were 2,127,286 shares of common stock outstanding, with 37.10% present or represented by proxy, constituting a quorum.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and shareholder voting outcomes.
Material Changes and Voting Results
Shareholders approved three key proposals at the Special Meeting:
- Proposal 1: Reverse Stock Split. Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split at a ratio between 1:4 and 1:40, to be determined by the Board.
- Votes For: 561,364
- Votes Against: 224,901
- Abstentions: 2,678
- Proposal 2: Nasdaq 20% Issuance. Stockholders approved the issuance of shares under a securities purchase agreement with C/M Capital Master Fund, LP (dated December 12, 2024), waiving the exchange cap to comply with Nasdaq Listing Rules 5635(a) and 5635(d).
- Votes For: 124,631
- Votes Against: 73,764
- Abstentions: 1,095
- Broker Non-Votes: 589,723
- Proposal 3: Adjournment. Stockholders approved the authority to adjourn the meeting to solicit additional proxies if necessary. This was not required as the other proposals passed.
- Votes For: 598,521
- Votes Against: 187,750
- Abstentions: 2,942
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, or specific risks beyond the context of the voting proposals. The approval of the reverse stock split suggests the company is taking action to maintain compliance with Nasdaq listing standards regarding share price or volume, though the specific ratio and timing remain at the Board's discretion.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once announced by the Board of Directors.
- Review the terms of the securities purchase agreement with C/M Capital Master Fund, LP, to understand the volume of shares to be issued under the approved 20% issuance proposal.
- Monitor Nasdaq compliance status to confirm the reverse split resolves any listing deficiencies.
- Check for subsequent filings regarding the implementation of the reverse stock split.